RESEARCH PAPER

Drug Safety Evaluation Using Real World Adverse Event Patterns

Suleiman Mohammad [1,2]*, Asokan Vasudevan [3,4], Hanan Jadallah[5]

[1]*Electronic Marketing and Social Media, Economic and Administrative Sciences Zarqa University, Jordan.*
[2]*Research follower, INTI International University, 71800 Negeri Sembilan, Malaysia.*
dr_sliman@yahoo.com, 0000-0001-6156-9063
[3]*Faculty of Business and Communications, INTI International University, 71800 Negeri Sembilan, Malaysia.*
[4]*Shinawatra University, 99 Moo 10, Bangtoey, Samkhok, Pathum Thani 12160 Thailand*
asokan.vasudevan@newinti.edu.my
[5]*Electronic Marketing and Social Media, Economic and Administrative Sciences Zarqa University, Jordan.*
Hananjadallah1987@gmail.com, 0009-0005-7138-1167

Received: 24th Aug, 2025; Revised: 24th Sep 2025; Accepted: 15th Nov, 2025; Available Online: 30th Nov, 2025

Abstract
The study involves pharmacovigilance databases, electronic health records, and published trial evidence to determine infrequent toxicity pattern, confirm organ-specific patterns of injury and detect responses of delayed onset. Mechanical plausibility was achieved with the testing of drug interactions signaling with systematic biochemical laboratory signals, including ALT, creatinine, troponin, and INR. The isolation of regional clusters of adverse events was achieved through reporting networks such as FAERS, VigiBase, EudraVigilance, and they determine genetic predispositions and sociocultural risk factors. In a variety of populations, comparative cohort designs separated true safety signals and spurious associations to improve causal inferences. The outcome demonstrates the relevance of the comorbidity profiling, longitudinal monitoring of exposure and geospatial mapping in identifying high-risk groups of patients. Altogether, the present work demonstrates that the multidimensional secondary strategies may be employed to develop the robust evidence-based regulatory recommendations, clinical decision-making and therapy-specific strategies to improve global pharmacovigilance and patient safety outcomes.

Keywords: Adverse events, Toxicity, Hepatotoxicity, Pharmacovigilance, comorbidity
How to cite this article: Mohammad S; Vasudevan A; Jadallah H; Drug safety evaluation using real world adverse event patterns. Int J Drug Deliv Technol. 2025;15(4): 1840-1852 , DOI: 10.25258/ijddt.15.4.37
Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Real world adverse event patterns are used to evaluate drug safety, and facilitate the accurate decision-making in pharmacovigilance. Real world datasets are a collection of heterogeneous patient responses in normal clinical settings. Examples of such datasets are electronic health records of pharmaceutical histories and clinical performances. The entries of adverse events offer time connections between drug exposure and the appearance of symptoms. Such connections help clinicians detect the signs of rare toxicity earlier. Clinical classification terminologies allow systematic documentation of organ local toxicities. Grading scales are used in the interpretation of reaction severity. The longitudinal patient records show cumulative effects associated with the chronic therapies. Comorbidity profiles put emphasis on risk escalators of susceptible groups of patients. Laboratory indices are biochemical changes related to a definite pharmacodynamic interaction. The structural abnormalities appear in imaging findings that are documented after the personal continuous administration of the drug. Genomic markers demonstrate patterns of susceptibility that determine patient specific drug reactions. Organized surveillance systems enhance the detection of delayed onset responses. The signal detection algorithms are used to filter noise in the complex safety datasets. These algorithms create proportionality measures used to direct additional clinical evaluation. Multiregional reporting networks increase the visibility of the geographically grouped adverse events. Comparative cohort analysis makes the difference between drug related signals and background clinical variability. Integrated evaluation models are the models that combine biological plausibility with the reported patient history. The models facilitate optimal therapeutic decision-making processes that assist in safe medication management in clinical environments.

MATERIALS AND METHODS

Data Source Identification

The secondary data were sourced by using the well-established pharmacovigilance databases, such as FDA Adverse Event Reporting System (FAERS), WHO VigiBase, and EudraVigilance. Additional data were peer-reviewed clinical trial publications, electronic health records, and national drug registries [1,2,3]. The criteria used in the selection included completeness, longitudinal coverage and the inclusion of biochemical laboratory markers. This guaranteed a wide range of representation of

**Author for Correspondence: dr_sliman@yahoo.com*

patient groups, classes of therapies and signs of adverse events in different geographic areas.

Data Extraction and Standardization

Structured query protocols were used to obtain adverse event reports, laboratory values, and comorbidity profiles. The variables were drug name, dosage, duration, biochemical markers, and clinical outcomes, which were standardized on the basis of MedDRA terminology [4,5,6]. Duplication of entries was eliminated and gaps were dealt with by imputation techniques. This standardization made it possible to cross-compare trial data and real-world registries, and this consistency ensured that adverse events were classified and organ-specific patterns of injury appeared.

Analytical Framework Application

The standardized datasets were evaluated using comparative cohort analyses, signal detection algorithms, and geospatial clustering. The statistical methods were estimation of hazard ratios, propensity score matching, and regression. Drug interaction signals were checked using laboratory markers like ALT, creatinine, troponin, and D - dimer [7,8,9]. Spatial epidemiology was used to isolate regional clusters of adverse events and longitudinal exposure timelines were used to track delayed onset responses.

Validation and Critical Appraisal

The results were confirmed by triangulation of various secondary sources that comprised clinical trial meta-analyses, registry data, and pharmacogenomic studies. The biochemical evidence, comparative cohorts, and mechanistic plausibility were used to distinguish true safety signals and spurious associations [10,11,12]. The limitations that were highlighted in critical appraisal included reporting bias, confounding comorbidities, and heterogeneity in the quality of data. This was a measure to make findings strong so as to give regulatory advice and clinical judgment during drug safety appraisal.

Result

Detection of rare toxicity patterns across routine clinical populations

The rare patterns of toxicity can only be detected through the combination of post-marketing surveillance, electronic health records and pharmacovigilance registries. Although rigorous, clinical trials tend to underrepresent a broad population and cannot detect delayed adverse events or low-frequency events. There is evidence in real-life, showing that statin users are susceptible to hepatotoxicity, and high alanine amino-transferase (ALT), jaundice, and cholestatic injury patterns are not always recorded in phase III studies [13,14,15]. The same case was also observed with cerivastatin rhabdomyolysis, which was detected by spontaneous reporting systems, with high levels of creatine kinase, myoglobinuria, and acute renal failure. Cumulative oxaliplatin induced peripheral neuropathy has been shown in oncology groups with paresthesia, dysesthesia and electromyographic abnormalities developing following chronic exposure [16]. Through echocardiographic follow-up over extended intervals, cardiotoxicity caused by trastuzumab was identified as left ventricles dysfunction with no signs or symptoms and overt congestive heart failure in patients with breast cancer.

Drug/Class	**Rare Toxicity Pattern**	**Clinical Signs/Markers**	**Evidence Source (Trials/ Registries)**	**Mechanistic Notes / Ingredients**
Statins (Atorvastatin, Simvastatin, Cerivastatin)	Hepatotoxicity, Rhabdomyolysis	↑ ALT/AST, jaundice, creatine kinase elevation, myoglobinuria, acute renal failure	FAERS, post-marketing surveillance, spontaneous reports	Lipophilic statins increase hepatic metabolism burden; cerivastatin withdrawn due to high rhabdomyolysis incidence
Oxaliplatin (Oncology)	Cumulative peripheral neuropathy	Paresthesia, dysesthesia, abnormal EMG findings	Oncology cohort studies, phase III follow-ups	Platinum-based DNA crosslinking agent; neurotoxicity linked to axonal degeneration
Trastuzumab (HER2 therapy)	Delayed cardiotoxicity	↓ LVEF, BNP elevation, overt CHF, asymptomatic LV dysfunction	Longitudinal echocardiographic monitoring	Monoclonal antibody targeting HER2; cardiotoxicity via HER2 blockade in cardiac tissue [17]
Carbamazepine	Severe cutaneous hypersensitivity	Stevens-Johnson syndrome, toxic epidermal necrolysis,	Pharmacogenomic studies, Asian registries	HLA-B*1502 allele predisposition; aromatic anticonvulsant

		eosinophilia		metabolism triggers immune-mediated reactions
Amiodarone	Pulmonary fibrosis	Radiographic honeycombing, ↓ DLCO, progressive dyspnea	Longitudinal cohort studies	Iodine-rich antiarrhythmic; induces oxidative stress and alveolar damage
Warfarin (Anticoagulant)	Intracranial hemorrhage clusters	Acute neurological deficits, seizures, impaired consciousness	Anticoagulant registries, elderly cohorts	Vitamin K antagonist; narrow therapeutic index, age-related pharmacokinetics
GLP-1 receptor agonists (Exenatide, Liraglutide)	Pancreatitis	Abdominal pain, ↑ amylase, radiological pancreatic inflammation	Diabetes registries, post-marketing data	Incretin mimetics; pancreatic enzyme dysregulation linked to receptor stimulation [18]
Isoniazid (Anti-TB)	Hepatotoxicity	Hyperbilirubinemia, hepatomegaly, impaired synthetic function	TB treatment registries, cohort studies	Hydrazine metabolite induces oxidative stress and hepatocellular necrosis

Table 1: Detection of Rare Toxicity Patterns Across Routine Clinical Populations

Evidence of pharmacogenomic has enhanced the detection of rare toxicity such as the case of HLA-B*1502-linked carbamazepine hypersensitivity, characterized by Stevens-Johnson syndrome, toxic epidermal necrolysis, and eosinophilic drug reactions. A longitudinal cohort study has reported pulmonary fibrosis associated with amiodarone treatment with radiographic honeycombing, decreased diffusing capacity and progressive dyspnea [19].



Figure 1: Flowchart of decision-making regarding OAC resumption in patients with recent ICH [20]

Clusters of intracranial hemorrhage in old age warfarin patients have been identified in the anticoagulant registries and these show up with acute neurological impairments, seizures, and impaired consciousness. GLP-1 receptor agonists also have been linked to pancreatitis which is manifested by pain in the abdominal region, increase in serum amylase, and radiographically defined heat in the pancreas [21]. Isoniazid hepatotoxicity is one of the most important indicators of tuberculosis medication and clinical signs in this condition are hyperbilirubinemia, hepatomegaly, and synthetic dysfunction.

An early warning regarding rare toxicity signals is achieved through the integration of the spontaneous adverse event reporting, electronic health record mining, and genomic screening. The findings are used to update regulatory labels, reinforce clinical aspects of monitoring protocols, and improve patient safety in the face of heterogeneous populations.

Identification of high risk patient groups using comorbidity profiles

Comorbidity profiling offers an organized means of determining high-risk groups of patients at increased risk of toxicity with drugs. Diabetic patients are also more vulnerable to nephrotoxicity caused by aminoglycosides and proteinuria, elevated serum creatinine, and decreased glomerular filtration rate are clinical symptoms of nephrotoxicity [22]. Hypertensive groups present more frequent incidences of renal impairment caused by NSAID

with increased levels of blood pressure, impaired renal perfusion, and progressive azotemia. The elderly patients with atrial fibrillation have increased risk of bleeding during anticoagulant therapy with hematuria, gastrointestinal bleeding, and intracranial hemorrhage supported by endoscopy and neuroimaging.



Figure 2: Non-steroidal Anti-inflammatory Drugs Market Size, 2022-2028 [23]

Patients with hepatic metastases of cancer are prone to chemotherapy-induced hepatotoxicity, which is characterized by hyperbilirubinemia, increased transaminases, and a disrupted coagulation profile. Non-selective beta-blockers increase bronchospasm in asthmatic populations with wheezing, dyspnea, and low peak expiratory volumes observed in respiratory assessment [24]. The lithium toxicity is exaggerated in patients with chronic kidney disease, and close therapeutic drug surveillance is necessary to detect tremors, confusion, and high serum lithium levels are present. There is increased thromboembolic risk in obese populations using hormonal contraceptives as manifested in deep vein thrombosis, pulmonary embolism and high D-dimer levels through Doppler ultrasonography and CT angiography.

Drug/Class	***Rare Toxicity Pattern***	***Clinical Signs/Markers***	***Evidence Source (Trials/Registries)***	***Mechanistic Notes / Ingredients***
Statins (Atorvastatin, Simvastatin, Cerivastatin)	Hepatotoxicity, Rhabdomyolysis	↑ ALT/AST, jaundice, creatine kinase elevation, myoglobinuria, acute renal failure	FAERS, post-marketing surveillance, spontaneous reports	Lipophilic statins increase hepatic metabolism burden; cerivastatin withdrawn due to high rhabdomyolysis incidence
Oxaliplatin (Oncology)	Cumulative peripheral neuropathy	Paresthesia, dysesthesia, abnormal EMG findings	Oncology cohort studies, phase III follow-ups	Platinum-based DNA crosslinking agent; neurotoxicity linked to axonal degeneration
Trastuzumab (HER2 therapy)	Delayed cardiotoxicity	↓ LVEF, BNP elevation, overt CHF, asymptomatic LV dysfunction	Longitudinal echocardiographic monitoring	Monoclonal antibody targeting HER2; cardiotoxicity via HER2 blockade in cardiac tissue
Carbamazepine	Severe cutaneous hypersensitivity	Stevens-Johnson syndrome, toxic epidermal necrolysis, eosinophilia	Pharmacogenomic studies, Asian registries	HLA-B*1502 allele predisposition; aromatic anticonvulsant metabolism triggers immune-mediated reactions
Amiodarone	Pulmonary fibrosis	Radiographic honeycombing, ↓ DLCO, progressive dyspnea	Longitudinal cohort studies	Iodine-rich antiarrhythmic; induces oxidative stress and alveolar damage [25]
Warfarin (Anticoagulant)	Intracranial hemorrhage clusters	Acute neurological deficits, seizures, impaired	Anticoagulant registries, elderly cohorts	Vitamin K antagonist; narrow therapeu

		consciousness		tic index, age-related pharmacokinetics
GLP-1 receptor agonists (Exenatide, Liraglutide)	Pancreatitis	Abdominal pain, ↑ amylase, radiological pancreatic inflammation	Diabetes registries, post-marketing data	Incretin mimetics; pancreatic enzyme dysregulation linked to receptor stimulation
Isoniazid (Anti-TB)	Hepatotoxicity	Hyperbilirubinemia, hepatomegaly, impaired synthetic function	TB treatment registries, cohort studies	Hydrazine metabolite induces oxidative stress and hepatocellular necrosis

Table 2: Detection of Rare Toxicity Patterns Across Routine Clinical Populations

Antiretroviral therapy has been shown to be more hepatotoxic in patients with HIV-positive status that has clinical manifestation involving jaundice, hepatic steatosis and high ALT/AST. Risk is additionally complicated by polypharmacy in the old populations with drug-drug interactions causing delirium, orthostatic hypotension and electrolyte imbalances [26]. Predictive modeling of adverse drug reactions is made possible by comorbidity-based stratification that is facilitated by information on electronic health records and registries.



Figure 3: Social Phenotyping for Cardiovascular Risk Stratification in Electronic Health Registries [27]

This profiling is used to inform personalized therapeutic interventions, regulations and clinical decision making. With the implementation of comorbidity indices, laboratory biomarkers, and imaging results, clinicians can actively determine vulnerable groups of patients, optimize drug dosage, and reduce the negative outcomes that can be circumvented.

Confirmation of organ specific injury trends through structured clinical markers

Trends of organ-specific injury are becoming established using systematic clinical indicators that come as a result of laboratory tests, imaging and pharmacovigilance data. The hepatotoxicity is a crucial indicator in various classes of drugs. Overdose of acetaminophen causes dose-related hepatic necrosis which is confirmed by increased alanine aminotransferase (ALT), aspartate aminotransferase (AST) and delayed prothrombin time [28].



Figure 4: Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma [19]

Liver injury in case of isoniazid is hepatomegaly and hyperbilirubinemia, cholestatic, and the biopsy shows centrilobular necrosis. Idiosyncratic hepatotoxicity is evidenced with statins, especially atorvastatin and simvastatin, and serum monitoring of ALT and alkaline phosphatase diagnoses the trends of injury [29]. Aminoglycosides like gentamicin are often associated with nephrotoxicity and such a condition is characterized by serum creatinine, blood urea nitrogen and decreased glomerular filtration rate as structured markers. Renal injury caused by Cisplatin is evidenced by hypomagnesemia, tubular necrosis on histology, and proteinuria. Structured markers of renal impairment in the NSAIDs, like ibuprofen and diclofenac, show trends of renal impairment in terms of decreased renal perfusion, increased serum potassium and progressive azotemia.

Cardiotoxicity is apparent in anthracycline therapy specifically doxorubicin, structured markers of which include decreased left ventricular ejection fraction, troponin elevation and echocardiographic alterations of the wall

motion. Cardiotoxicity associated with trastuzumab is established by serial echocardiography and increase of brain natriuretic peptide (BNP) [30]. The tendencies of pulmonary damage are validated in the amiodarone treatment, and the systematic signs encompassed diminished diffusing capacity of the lungs to carbon monoxide (DLCO), radiographic honeycombing, and advancing dyspnea. Patterns of restrictive spirometry, hypoxemia and interstitial infiltrates on CT confirm pulmonary fibrosis caused by bleomycin. The trends of hematological injury are observed in the case of clozapine-induced agranulocytosis, was proved by the systematic observation of the absolute neutrophil counts. The Aplastic anemia induced by carbamazepines is established by use of pancytopenia, bone marrow biopsy, and reticulocyte suppression. Structured clinical markers, in turn, are reproducible confirmation of organ-specific injury patterns, allowing regulation warnings, personalized monitoring, and enhanced therapeutic safety in a wide range of drugs.

Recognition of delayed onset reactions through longitudinal exposure tracking

Delayed onset adverse reactions are becoming increasingly known because of longitudinal exposure monitoring across electronic health records, registries, and long-term clinical trials. The evidence of amiodarone delayed pulmonary toxicity with fibrosis occurring after months of treatment has been demonstrated by progressive dyspnea, decreasing DLCO, and radiographic interstitial changes. Hepatic fibrosis due to methotrexate arises following a long-term low-dose administration, where organized surveillance displays become high ALT, low albumin, and biopsy-proven periportal fibrosis [31]. Alendronate and zoledronic acid are the bisphosphonates that have been shown to have delayed osteonecrosis of the jaw, which is identified by longitudinal dental records with exposed necrotic bone, pain, and secondary infection. Olanzapine and risperidone as antipsychotics are shown to exhibit a slowed metabolic syndrome, and longitudinal follow-ups indicate increasing weight gain, hyperglycemia, dyslipidemia and insulin resistance. Long-term echocardiographic studies indicate that the chemotherapeutic agents like cyclophosphamide exhibit slower cardiotoxicity and as the months pass, left ventricular dysfunction, arrhythmias, and high levels of troponin are observed months after exposure. Cisplatin has delayed ototoxicity and audiometric surveillance has enabled progressive sensorineural hearing loss.

Drug/ Class	***Organ System Affected***	***Injury Trend / Type***	***Structured Clinical Markers***	***Evidence Source (Trials/ Registries)***	***Mechanistic Notes***
Acetaminophen (Paracetamol)	Liver (Hepatic)	Dose-dependent hepatic necrosis	↑ ALT/AST, prolonged PT/INR, hepatic biopsy necrosis	Overdose case registries, toxicology studies	Reactive metabolite (NAPQI) depletes glutathione, causing hepatocellular necrosis
Isoniazid (Anti-TB)	Liver (Hepatic)	Idiosyncratic hepatotoxicity	Hyperbilirubinemia, hepatomegaly, cholestatic injury	TB treatment registries, cohort studies	Hydrazine metabolite induces oxidative stress and hepatocellular injury
Statins (Atorvastatin, Simvastatin)	Liver (Hepatic)	Idiosyncratic hepatotoxicity	↑ ALT, ↑ alkaline phosphatase, jaundice	FAERS, post-marketing surveillance	Lipophilic statins increase hepatic metabolic burden
Gentamicin (Aminoglycoside)	Kidney (Renal)	Nephrotoxicity	↑ Serum creatinine, ↑ BUN, ↓ GFR	Clinical nephrology registries	Accumulation in proximal tubules causes necrosis
Cisplatin (Chemotherapy)	Kidney (Renal)	Tubular necrosis, electrolyte imbalance	Hypomagnesemia, proteinuria, histological tubular necrosis	Oncology cohorts, renal monitoring	Platinum compound damages renal tubular epithelium

NSAIDs (Ibuprofen, Diclofenac)	Kidney (Renal)	Renal impairment	↑ Serum potassium, ↓ renal perfusion, progressive azotemia	Post-marketing registries, EHRs	Inhibition of prostaglandins reduces renal blood flow
Doxorubicin (Anthracycline)	Heart (Cardiac)	Cumulative cardiotoxicity	↓ LVEF, ↑ troponin, echocardiographic wall motion abnormalities	Oncology trials, long-term follow-ups	Free radical generation damages cardiomyocytes
Trastuzumab (HER2 therapy)	Heart (Cardiac)	Cardiotoxicity	↓ LVEF, ↑ BNP, asymptomatic LV dysfunction	Breast cancer registries, echocardiography	HER2 blockade impairs cardiac repair pathways
Amiodarone (Antiarrhythmic)	Lung (Pulmonary)	Pulmonary fibrosis	↓ DLCO, radiographic honeycombing, progressive dyspnea	Longitudinal cohort studies	Iodine-rich drug induces oxidative alveolar damage
Bleomycin (Chemotherapy)	Lung (Pulmonary)	Pulmonary fibrosis	Restrictive spirometry, hypoxemia, CT interstitial infiltrates	Oncology registries, imaging studies	Free radical damage to pulmonary tissue
Clozapine (Antipsychotic)	Hematological	Agranulocytosis	↓ Absolute neutrophil count (ANC), pancytopenia	Psychiatric registries, hematology monitoring	Immune-mediated bone marrow suppression
Carbamazepine (Anticonvulsant)	Hematological	Aplastic anemia	Pancytopenia, bone marrow biopsy, ↓ reticulocytes	Pharmacovigilance reports, cohort studies	Aromatic anticonvulsant metabolism triggers marrow suppression

Table 3: Confirmation of Organ Specific Injury Trends through Structured Clinical Markers

There is a delay in onset of mitochondrial toxicity with the use of antiretroviral therapy, specifically the nucleoside reverse transcriptase inhibitors which include zidovudine, which has been proven to cause lactic acidosis, myopathy, and increase lactate levels with protracted use. Delayed pancreatitis has been identified in longitudinal registries during the treatment with GLP-1 receptor agonists, where recurrent abdominal pain, the presence of high levels of amylase, and the presence of radiological evidence of pancreatic inflammation appears following prolonged exposure. Immunosuppressive agents, including nivolumab and pembrolizumab, have immune checkpoint inhibition that is delayed, which has been observed by longitudinal follow-up to show hypothyroidism, adrenal deficiency, and hypophysitis, as indicated by a reduction in thyroid hormones, cortisol deficiency, and pituitary enlargement [32]. The most effective way of identifying delayed onset reactions is using structured longitudinal tracking that incorporates laboratory biomarkers, imaging, and patient-reported outcomes. This kind of tracking ensures cumulative toxicity trends, helps in early intervention and provides background on long-term regulatory policy. Systematic monitoring of prolonged exposure helps clinicians to predetermine adverse events delays, streamline therapeutic-regimen, and protect patient outcomes.

Verification of drug interaction signals using biochemical laboratory changes

The signal of drug interaction verification is pegged on the structured biochemical laboratory monitoring to ascertain the mechanistic plausibility and clinical relevance. This may be demonstrated by warfarin amiodarone interaction, where high international normalized ratio (INR), prothrombin time and increased risk of bleeding were confirmed in serial coagulation tests. Rifampicin-oral contraceptive interaction evidences a decrease in plasma estrogen and progesterone levels and results in a breakthrough bleeding and contraceptive failure. Statin-macrolide antibiotic drug interactions, especially simvastatin and clarithromycin, result in increased creatine kinase, myoglobinuria and acute renal failure, thereby confirming the presence of rhabdomyolysis. The presence

of methotrexate-NSAID interactions is confirmed through an increase in serum creatinine, decrease in glomerular filtration rate and the rise in the plasma concentrations of methotrexate, which result in mucositis and pancytopenia [33]. Interaction between digoxin and verapamil is validated by increased serum digoxin levels, bradyarrhythmias and protruded PR interval on the electrocardiogram. The interaction of lithium and angiotensin converting enzyme indicates a high serum concentration of lithium, tremors, confusion, and nephrogenic diabetes insipidus that have been verified by electrolyte tests.

Drug A + Drug B → Biochemical Change → Clinical Sign → Safety Signal

Warfarin + Amiodarone → ↑ INR / ↑ PT → Bleeding, hematuria, intracranial hemorrhage

Methotrexate + NSAID → ↑ Creatinine / ↓ GFR → Mucositis, pancytopenia, nephrotoxicity

Statin + Clarithromycin → ↑ CK / Myoglobinuria → Muscle pain, rhabdomyolysis, acute renal failure

Digoxin + Verapamil → ↑ Serum Digoxin → Bradyarrhythmia, PR prolongation, dizziness

Lithium + ACE Inhibitor → ↑ Serum Lithium → Tremors, confusion, nephrogenic diabetes insipidus

Clopidogrel + PPI → ↓ Active Metabolite / ↓ Platelet Aggregation → Thrombosis, myocardial infarction

Biochemical assays are used to confirm the interaction between cytochrome P450. The interaction of ketoconazole and cyclosporine increases the levels of cyclosporine troughs leading to nephrotoxicity, hypertension and hyperkalemia. The interaction between grapefruit juice and felodipine raises plasma felodipine levels, which are established through hypotension, dizziness, and high levels of hepatic enzymes involved in an inhibition test. The interactions of antiretroviral with antitubercular drugs, efavirenz-rifampicin, show decreased efavirenz plasma levels, which is evidenced by therapeutic drug monitoring and viral load rebound. The interaction of proton and pump inhibitors with clopidogrel decreases the active metabolites formation, which are determined by platelet aggregation tests and raised thrombotic events. Drug interaction signals are not spurious because verification is done by a series of biochemical laboratory changes [34]. Mechanistic pathways are confirmed by structured determination of serum drug levels, enzyme activity, coagulation profiles, and renal functions. The findings are used to regulate labeling, clinically in decision-making, and tailor treatment to reduce negative consequences.

Isolation of regional adverse event clusters from reporting networks

Clustering of adverse events at the regional level needs to be isolated using a systematic approach of analyzing pharmacovigilance reporting networks that include spontaneous reports, hospital registries, and national surveillance systems. South Asian population has shown regional clustering of hepatotoxicity, especially in the case of isoniazid and rifampicin, which has been confirmed by high ALT, AST and hyperbilirubinemia. Pharmacovigilance networks in Europe identified areas of fluoroquinolone-associated tendon rupture, with Achilles tendon pain, swelling and partial tears confirmed by MRI [35]. The opioid-induced respiratory depression showed regional aggregation in North American registries and the use of naloxone, hypoxemia, and high carbon dioxide level ensured negative indicators. The clusters of Stevens-Johnson syndrome with carbamazepine were identified through Japanese reporting network and biopsy-proven epidermal necrosis and confirmed by mucocutaneous lesions and eosinophilation. African pharmacovigilance systems evidenced regional clustering of nevirapine induced hepatotoxicity and the presence of jaundice, high transaminases and hepatic steatosis were proven by imaging.

Region / Population	Drug/Class	Adverse Event Cluster	Clinical Signs / Structured Markers	Evidence Source (Registries/Networks)	Mechanistic / Contextual Notes
South Asia	Isoniazid, Rifampicin (Anti-TB)	Hepatotoxicity	↑ ALT/AST, hyperbilirubinemia, hepatomegaly	National TB registries, FAERS, WHO VigiBase	Genetic polymorphisms in NAT2 acetylation increase hepatotoxic risk
Europe	Fluoroquinolones (Ciprofloxacin, Levofloxacin)	Tendon rupture clusters	Achilles tendon pain, swelling, MRI-confirmed partial tears	EudraVigilance, hospital registries	Collagen degradation linked to fluoroquinolone exposure; higher reporting density in EU
North America	Opioids (Morphine, Oxycodone,	Respiratory depression clusters	Hypoxemia, hypercapnia, naloxone	FDA FAERS, US hospital surveillance	Regional prescribing patterns and

	Fentanyl)		administration		misuse trends amplify cluster visibility
Japan	Carbamazepine (Anticonvulsant)	Stevens-Johnson syndrome clusters	Mucocutaneous lesions, eosinophilia, biopsy-proven epidermal necrosis	Japanese pharmacovigilance networks	HLA-B*1502 allele prevalence drives hypersensitivity clustering
Africa	Nevirapine (Antiretroviral)	Hepatotoxicity clusters	Jaundice, ↑ transaminases, hepatic steatosis	African HIV registries, WHO VigiBase	Genetic and nutritional cofactors influence hepatotoxicity prevalence
Latin America	Chloroquine, Hydroxychloroquine	Retinopathy clusters	Fundoscopic changes, visual field defects, OCT abnormalities	Regional malaria registries, ophthalmology networks	Long-term prophylaxis use increases cumulative retinal toxicity
Global (multi-regional)	GLP-1 receptor agonists (Exenatide, Liraglutide)	Pancreatitis clusters	Abdominal pain, ↑ amylase, radiological pancreatic inflammation	Diabetes registries, WHO VigiBase	Regional dietary factors and obesity prevalence influence clustering

Table 4: Isolation of Regional Adverse Event Clusters from Reporting Networks

Clustering is dependent on regional dietary and genetic factors. Carbamazepine hypersensitivity was more frequent in Asian populations with HLA-B*1502 allele and statin-induced myopathy was more frequent in European cohorts by detection of elevated creatine kinase and electromyographic changes. The registries in Latin America found clusters of findings of chloroquine-induced retinopathy, which were confirmed by the fundal changes, visual field defects, and optical coherence tomography. Clusters isolation needs structured clinical marker validation, signal detection algorithms and geospatial mapping. WHO VigiBase, FDA FAERS, and EudraVigilance integration will allow detecting adverse event patterns that are geographically specific [36]. Such findings facilitate regulatory alerts at the regional level, personalized genetic screening and culturally tailored clinical monitoring measures.

Differentiation of true safety signals using comparative cohort analyses

The true safety signals have to be further differentiated by conducting a comparative cohort study in the exposed and unexposed groups adjusting confounding factors. The risk of statin-associated diabetes was determined by comparing follow-up cohorts, where high fasting glucose, HbA1c and incidences of new onset diabetes were validated in exposed cohorts. Metabolic syndrome brought about by antipsychotics was confirmed by comparative studies with cohorts of olanzapine with greater weight gain, hyperlipidemia, and insulin resistance than risperidone or haloperidol. Gastrointestinal bleeding related to NSAID was verified using comparative cohorts and exposed patients showed a higher rate of melena, hematemesis, and endoscopic ulceration [37]. The interaction between proton pump inhibitor and clopidogrel was distinguished as a true signal with exposure cohorts demonstrating higher rates of myocardial infarction, which had been verified through troponin raising and angiographic thrombosis.

True Safety Signal=(Exposed Cohort Clinical Marker Mean−Control Cohort Clinical Marker Mean)÷Variance Adjustment

$\Delta HbA1c = HbA1c_{\text{Statin Cohort}} - HbA1c_{\text{Non-Statin Cohort}} \Rightarrow$ Signal: New-Onset Diabetes

Comparative studies of exposure levels of fluoroquinolone validated the tendon rupture signals, whereby Achilles tendon tears, pain, and MRI abnormalities were higher than non-exposure groups. Co-hort antiretroviral therapy distinguished between lactic acidosis signals, and patients receiving zidovudine exhibited high lactate levels, metabolic acidosis, and myopathy in comparison to other regimens. The cardiotoxicity resulting after chemotherapy was verified by use of comparative cohorts, where the anthracycline-treated patients showed a lower ejection

fraction, increased troponin and acutely suffered heart failure in comparison with non-anthracycline therapies. Nephrotoxicity due to lithium was confirmed by comparative cohort studies which demonstrated increased creatinine levels, decreased level of GFR and chronic interstitial nephritis in exposed patients relative to the use of other mood stabilizers [38]. Differentiation needs systematic statistical techniques, such as propensity score matching, estimation of hazard ratios, and sensitivity analysis. Comparative cohort designs overcome spurious associations, establish causality and build up regulatory confidence in safety signals. Clinical monitoring, therapeutic substitution as well as evidence-based pharmacovigilance policy are guided by these findings.

DISCUSSION

The strengths and the limitations of the existing pharmacovigilance practice are demonstrated by verification of drug interaction signals by biochemical laboratory changes. Although the objective evidence of suspected interactions offered by laboratory tests, e.g., serum drug concentrations, coagulation profiles, and renal function markers, can be used, relying on these markers could simplify more complex pharmacokinetic and pharmacodynamic interactions. As an illustration, the interaction of warfarin and amiodarone is always confirmed with high levels of INR and the risk of bleeding, but this is complicated by diet and genetic polymorphisms in CYP2C9, as well as simultaneous drugs. Equally, interactions of methotrexate with NSAIDs exhibit nephrotoxicity which is manifested by increased creatinine yet renal disease or dehydration may amplify laboratory results [39] . The key problem is that it is important to differentiate between clinically meaningful interactions and temporary biochemical changes. Excessive attention to the laboratory markers may lead to false positives, whereas the modest changes remain unnoticed, and intervention is delayed. Mechanistic studies and comparative cohort analyses of biochemical signals are needed so that an increase in creatine kinase in statin-macrolide interactions is indicative of rhabdomyolysis and not benign muscle pain. In such a way, although the biochemical laboratory changes cannot be ignored in the verification, they need to be combined with the clinical outcomes, pharmacogenomic, and longitudinal monitoring to form strong causality. This breadth of approach fortifies regulatory trust, decreases undue therapy relinquishment and patient safety due to evidence-based signal confirmation.

Future implication

The analysis of adverse events signals is based on the critical review of the adverse events, which testifies that multidimensional approaches are fundamental to contemporary pharmacovigilance. Systematic observation of the biochemical indices, longitudinal exposure analysis and comparative cohort validation offers clinicians with practical means to foresee and alleviate drug-associated hazards [40]. The regional cluster analysis reveals that the specific approaches to population, such as genetic screening and culturally adjusted monitoring schemes, are needed. Drug interactions can be verified by laboratory assays, which timely intervene to minimize morbidity and mortality. Notably, the combination of the secondary data sources helps to bridge the gap between the controlled trial settings and the clinical practice. Such results support enhanced regulatory systems, more rigorous reporting practices, and individualized treatment plans, which ultimately enhance patient safety in drug therapy and increase patient outcomes in various healthcare systems.

CONCLUSION

In this research, it can be seen that secondary data analysis of pharmacovigilance networks, clinical trial repositories, and electronic health records can present powerful information regarding drug safety evaluation. The study demonstrates the relevance of organized clinical indicators in determining adverse signs, including ALT, creatinine, troponin, and D-dimer, since they detect unusual patterns of toxicity, confirm patterns of organ injury, and identify delayed responses. Comparative cohort analyses further distinguish between real safety issues and spurious relationships, whereas regional cluster isolation focuses on the contribution of genetic predisposition and sociocultural issues. Confirmation of drug interaction signals by changes in biochemical laboratory is a step to enhance mechanistic plausibility to guarantee clinical relevance. All these results highlight the need to combine laboratory and registries with trial evidence to improve patient safety and regulatory confidence.

Acknowledgement

This research was partially funded by Zarqa University..

REFERENCE

[1] Battini V, Van Manen RP, Gringeri M, Mosini G, Guarnieri G, Bombelli A, Pozzi M, Nobile M, Radice S, Clementi E, Carnovale C. The potential antidepressant effect of antidiabetic agents: new insights from a pharmacovigilance study based on data from the reporting system databases FAERS and VigiBase. Frontiers in pharmacology. 2023 Feb 17;14:1128387. Available at https://www.frontiersin.org/articles/10.3389/fphar.2023.1128387/full

[2] Mohammad AAS, Alolayyan MN, Al-Daoud KI, Al Nammas YM, Vasudevan A, Mohammad SI. Association between Social Demographic Factors and Health Literacy in Jordan. Journal of Ecohumanism. 2024;3:2351-2365.

[3] Mohammad AA, Shelash SI, Saber TI, Vasudevan A, Darwazeh NR, Almajali R. Internal audit governance factors and their effect on the risk-based auditing adoption of commercial banks in Jordan. Data and Metadata. 2025;4:464.

[4] Garmann T, Samdal H, Sartori D, Jahanlu D, Andersen F, Rocca E. Strategies and Challenges in Coding

Ambiguous Information Using MedDRA®: An Exploration Among Norwegian Pharmacovigilance Officers: T. Garman et al. Drug Safety. 2025 Jul 1:1-7. Available at https://link.springer.com/article/10.1007/s40264-025-01573-2

[5] Yaseen H, Al-Adwan AS, Nofal M, Hmoud H, Abujassar RS. Factors influencing cloud computing adoption among SMEs: The Jordanian context. Information Development. 2023;39: 317-332.

[6] Mohammad AAS, Al-Daoud KI, Rusho MA, Alkhayyat A, Doshi H, Dey P, Kiani M. Modeling polyethylene glycol density using robust soft computing methods. Microchemical Journal. 2025;210:112815.

[7] Fantin C, Aparecido PD, de Arruda Takano PK, Jucá TS, dos Santos Viana L. Alterations in the Results of Biochemical Laboratory Tests Due to the Administration of Antihypertensive Drugs. Journal of Pharmacy and Pharmacology. 2022;10:131-8. Available at https://www.davidpublisher.com/Public/uploads/Contribute/62577a338ee68.pdf

[8] Mohammad AAS. The impact of COVID-19 on digital marketing and marketing philosophy: evidence from Jordan. International Journal of Business Information Systems. 2025;48:267-281.

[9] Al-Rahmi WM, Al-Adwan AS, Al-Maatouk Q, Othman MS, Alsaud AR, Almogren AS, Al-Rahmi AM. Integrating communication and task–technology fit theories: The adoption of digital media in learning. Sustainability. 2023;15:8144.

[10] Hammad TA, Davis S, Afsar S. Exploring the scientific underpinnings of investigating safety signals: analytical insights in deciphering drug safety evidence. Frontiers in Drug Safety and Regulation. 2024 Aug 16;4:1445998. Available at https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2024.1445998/full

[11] Hujran O, Al-Debei MM, Al-Adwan AS, Alarabiat A, Altarawneh N. Examining the antecedents and outcomes of smart government usage: An integrated model. Government Information Quarterly. 2023;40:101783.

[12] Mohammad AAS, Mohammad SIS, Al-Daoud KI, Al Oraini B, Vasudevan A, Feng Z. Optimizing the Value Chain for Perishable Agricultural Commodities: A Strategic Approach for Jordan. Research on World Agricultural Economy. 2025;6:465-478.

[13] Alanazi NS, Alenazi TS, Alenzi KA. Hepatotoxicity induced by fluvastatin: a reversible acute cholestatic liver injury. The American Journal of Case Reports. 2021 Aug 12;22:e931418-1. Available at https://pmc.ncbi.nlm.nih.gov/articles/PMC8369431/

[14] Mohammad AA, Panda SK, Mohammad SI, Raja N, Panda N, Vasudevan A, Hunitie MF.A. Indigenous agricultural practices of the Paddari Tribe in Jammu and Kashmir: Insights for sustainable mountain farming. Pakistan Journal of Agricultural Research. 2025;38: 01-09.

[15] Shlash MA, Shelash MS, Al Oraini B, Ayman HA, Asokan VA, Turki AM. Decoding Consumer Behaviour: Leveraging Big Data and Machine Learning for Personalized Digital Marketing. Data & Metadata. 2025;4:700.

[16] Bird CM, Webb EK, Schramm AT, Torres L, Larson C, deRoon-Cassini TA. Racial discrimination is associated with acute posttraumatic stress symptoms and predicts future posttraumatic stress disorder symptom severity in trauma-exposed Black adults in the United States. Journal of traumatic stress. 2021 Oct;34(5):995-1004. Available at https://onlinelibrary.wiley.com/doi/abs/10.1002/jts.22670

[17] Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Current Oncology Reports. 2021 Nov;23(11):128. Available at https://link.springer.com/article/10.1007/s11912-021-01114-x

[18] Reed J, Bain SC, Kanamarlapudi V. The regulation of metabolic homeostasis by incretins and the metabolic hormones produced by pancreatic islets. Diabetes, Metabolic Syndrome and Obesity. 2024 Dec 31:2419-56. Available at https://www.tandfonline.com/doi/abs/10.2147/DMSO.S415934%4010.1080/tfocoll.2024.0.issue-pharmacotherapy

[19] Money DB, Lee DH, Hadar A, Doherty J, Malanga C, Serino A, Cohen AJ, Doherty JL. Amiodarone for the treatment of arrhythmias in COVID-19 patients does not increase the risk of pulmonary fibrosis: a retrospective cohort study. Cureus. 2023 Jan 23;15(1). Available at https://www.cureus.com/articles/133667-amiodarone-for-the-treatment-of-arrhythmias-in-covid-19-patients-does-not-increase-the-risk-of-pulmonary-fibrosis-a-retrospective-cohort-study.pdf

[20] Y. Li and G. Y. H. Lip, “Anticoagulation Resumption After Intracerebral Hemorrhage,” Current Atherosclerosis Reports, vol. 20, no. 7, May 2018, Available at https://link.springer.com/article/10.1007/s11883-018-0733-y

[21] Guo H, Guo Q, Li Z, Wang Z. Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis. Frontiers in Pharmacology. 2024 Nov 13;15:1461398. Available at https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1461398/full

[22] Kaur A, Sharma GS, Kumbala DR. Acute kidney injury in diabetic patients: a narrative review. Medicine. 2023 May 26;102(21):e33888. Available at https://journals.lww.com/md-journal/fulltext/2023/05260/Acute_kidney_injury_in_diabetic_patients__A.7.aspx?context=LatestArticles

[23] A. D'Souza and R. Singh, "Global Non-steroidal Anti-inflammatory Drugs Market Size, Share & Industry Trends Analysis Report By Route of Administration (Oral, Topical and Others), By Distribution Channel, By Route of Disease Indication, By Regional Outlook and Forecast, 2022 - 2028," KBV Research, Jul. 31, 2022. Available at https://www.kbvresearch.com/non-steroidal-anti-inflammatory-drugs-market/ (accessed Nov. 18, 2025).

[24] Preveden A, Todić M, Drljević-Todić V, Preveden M, Zdravković R, Zvezdin B. Use of beta blockers in patients with asthma and chronic obstructive pulmonary disease. Medicinski pregled. 2021;74(3-4):127-33. Available at https://doiserbia.nb.rs/Article.aspx?id=0025-81052104127P

[25] Karbownik-Lewińska M, Stępniak J, Iwan P, Lewiński A. Iodine as a potential endocrine disruptor—a role of oxidative stress. Endocrine. 2022 Nov;78(2):219-40. Available at https://link.springer.com/article/10.1007/s12020-022-03107-7

[26] Das B, Ramasubbu SK, Agnihotri A, Kumar B, Rawat VS. Leading 20 drug–drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients. Therapeutic Advances in Cardiovascular Disease. 2021 Nov;15:17539447211058892. Available at https://journals.sagepub.com/doi/abs/10.1177/17539447211058892

[27] R. Ibrahim, H. N. Pham, S. Ganatra, Z. Javed, K. Nasir, and Sadeer Al-Kindi, "Social Phenotyping for Cardiovascular Risk Stratification in Electronic Health Registries," Current Atherosclerosis Reports, vol. 26, no. 9, pp. 485–497, Jul. 2024, doi: Available at https://www.kbvresearch.com/non-steroidal-anti-inflammatory-drugs-market/

[28] Jain P, Batta AK, Singh P. Comparative study of serum levels of gamma-glutamyl transferase, Aspartate aminotransferase (AST), Alanine Transaminase (ALT), AST: ALT, and bilirubin in patients with chronic hepatitis. Indian Journal of Medical Biochemistry. 2023 Aug 25;26(3):73-6. Available at https://www.ijmb.in/abstractArticleContentBrowse/IJMB/46/26/3/33426/abstractArticle/Article

[29] C.-W. Huang et al., "Reappraisal of the Role of Alkaline Phosphatase in Hepatocellular Carcinoma," Journal of Personalized Medicine, vol. 12, no. 4, p. 518, Apr. 2022, doi: Available at https://www.mdpi.com/2075-4426/12/4/518

[30] Bie P. Plasma concentrations of peptide hormones: Unrealistic levels of vasopressin (AVP), oxytocin (OXT), and brain natriuretic peptide (BNP). Acta Physiologica. 2024 Sep;240(9):e14200. Available at https://onlinelibrary.wiley.com/doi/abs/10.1111/apha.14200

[31] Di Martino V, Verhoeven DW, Verhoeven F, Aubin F, Avouac J, Vuitton L, Lioté F, Thévenot T, Wendling D. Busting the myth of methotrexate chronic hepatotoxicity. Nature Reviews Rheumatology. 2023 Feb;19(2):96-110. Available at https://www.nature.com/articles/s41584-022-00883-4

[32] Langlois F, Varlamov EV, Fleseriu M. Hypophysitis, the growing spectrum of a rare pituitary disease. The Journal of Clinical Endocrinology & Metabolism. 2022 Jan 1;107(1):10-28. Available at https://academic.oup.com/jcem/article-abstract/107/1/10/6371009

[33] Lam SH, So H, Cheng IT, Li EK, Wong P, Li TK, Lee AP, Tam LS. Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis. Therapeutic Advances in Musculoskeletal Disease. 2021 Jun;13:1759720X211027712. Available at https://journals.sagepub.com/doi/abs/10.1177/1759720X211027712

[34] Kontsioti E, Maskell S, Anderson I, Pirmohamed M. Identifying Drug–Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects. Clinical Pharmacology & Therapeutics. 2024 Jul;116(1):165-76. Available at https://ieeexplore.ieee.org/abstract/document/9435097/

[35] Shu Y, Zhang Q, He X, Liu Y, Wu P, Chen L. Fluoroquinolone-associated suspected tendonitis and tendon rupture: a pharmacovigilance analysis from 2016 to 2021 based on the FAERS database. Frontiers in Pharmacology. 2022 Sep 6;13:990241. Available at

https://www.frontiersin.org/articles/10.3389/fphar.2022.990241/full

[36] Song Q, Gao S, Tan Y. Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system. The Journal of Headache and Pain. 2025 Jun 23;26(1):147. Available at https://link.springer.com/article/10.1186/s10194-025-02091-3

[37] Tawfik AG, Gomez-Lumbreras A, Del Fiol G, Kawamoto K, Trinkley KE, Reese T, Jones A, Malone DC. Nonsteroidal Anti-Inflammatory Drugs and Risk of Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Clinical Pharmacology & Therapeutics. 2025 Sep 7. Available at https://ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.70054

[38] Zhu N. Mental illness in chronic kidney disease: prognosis, drug utilization, and treatment outcomes. Karolinska Institutet (Sweden); 2024. Available at https://search.proquest.com/openview/3605122e8a2c32eda2cc2ec57267931d/1?pq-origsite=gscholar&cbl=2026366&diss=y

[39] Ahsan MU, Ambreen U, Javed H, Noor N, Jan M, Khan MN. NSAID-associated Renal Injury: Mechanisms, Risks, and Safer Strategies. Archives of Nephrology and Renal Studies. 2025 Jul 31;5(1):1-5. Available at https://www.scientificarchives.com/abstract/nsaid-associated-renal-injury-mechanisms-risks-and-safer-strategies

[40] Cui J, Zhang T, Zhang C, Xue Z, Chen D, Kong X, Zhao C, Guo Y, Li Z, Liu X, Duan J. Long-term exposure to low concentrations of polycyclic aromatic hydrocarbons and alterations in platelet indices: A longitudinal study in China. PLoS One. 2022 Nov 2;17(11):e0276944. Available at https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0276944.